Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700
Debt
Debt-to-Equity Ratio0.27
Current Ratio5.73
Quick Ratio3.89
Price-To-Earnings
Trailing P/E Ratio22.31
Forward P/E Ratio21.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$200.77 million
Price / Sales3.16
Cash Flow$1.0484 per share
Price / Cash14.26
Book Value$4.02 per share
Price / Book3.72
Profitability
EPS (Most Recent Fiscal Year)$0.67
Net Income$21.55 million
Net Margins11.49%
Return on Equity16.97%
Return on Assets11.62%
Miscellaneous
Employees640
Outstanding Shares42,400,000
Market Cap$635.93 million
Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience declared a quarterly dividend on Tuesday, July 24th. Shareholders of record on Friday, August 10th will be paid a dividend of $0.125 per share on Monday, August 20th. This represents a $0.50 annualized dividend and a yield of 3.34%. The ex-dividend date is Thursday, August 9th. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings results on Tuesday, July, 31st. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.17 by $0.01. The company had revenue of $51.74 million for the quarter, compared to analysts' expectations of $52.17 million. Meridian Bioscience had a net margin of 11.49% and a return on equity of 16.97%. The company's revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 EPS. View Meridian Bioscience's Earnings History.
When is Meridian Bioscience's next earnings date?
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $0.69-0.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.70. The company issued revenue guidance of $209-214 million, compared to the consensus revenue estimate of $212.19 million.
What price target have analysts set for VIVO?
1 equities research analysts have issued 12 month price objectives for Meridian Bioscience's stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Meridian Bioscience's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for Meridian Bioscience.
What is the consensus analysts' recommendation for Meridian Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF) and Fluoropharma Medical (FPMI).
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- Mr. John A. Kraeutler, Exec. Chairman (Age 70)
- Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
- Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
- Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 49)
- Mr. Lawrence J. Baldini, Exec. VP & Pres of Global Operations (Age 59)
Has Meridian Bioscience been receiving favorable news coverage?
Headlines about VIVO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Meridian Bioscience earned a news and rumor sentiment score of 0.24 on Accern's scale. They also gave press coverage about the company an impact score of 48.16 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Meridian Bioscience.
Who are Meridian Bioscience's major shareholders?
Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.94%), Renaissance Technologies LLC (6.21%), Dimensional Fund Advisors LP (4.32%), Systematic Financial Management LP (2.67%), Bank of New York Mellon Corp (1.92%) and Schwab Charles Investment Management Inc. (1.06%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Which major investors are selling Meridian Bioscience stock?
VIVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Schwab Charles Investment Management Inc., Alambic Investment Management L.P., BNP Paribas Arbitrage SA, American Century Companies Inc., GSA Capital Partners LLP, Bank of America Corp DE and BlueMountain Capital Management LLC. View Insider Buying and Selling for Meridian Bioscience.
Which major investors are buying Meridian Bioscience stock?
VIVO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Segall Bryant & Hamill LLC, Systematic Financial Management LP, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Bank of Montreal Can, Connor Clark & Lunn Investment Management Ltd. and Russell Investments Group Ltd.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy shares of Meridian Bioscience?
Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of VIVO stock can currently be purchased for approximately $14.95.
How big of a company is Meridian Bioscience?
Meridian Bioscience has a market capitalization of $635.93 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.67 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.
How can I contact Meridian Bioscience?
Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.
MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
